Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 6/2009

01-06-2009 | Concise Article

In vivo and in vitro detection of a superantigenic toxin Vbeta signature in two forms of streptococcal toxic shock syndrome

Authors: D. Thomas, T. Perpoint, O. Dauwalder, G. Lina, B. Floccard, J.-C. Richard, A. Bouvet, D. Peyramond, B. Allaouchiche, C. Chidiac, F. Vandenesch, J. Etienne, T. Ferry

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 6/2009

Login to get access

Abstract

The aim of this study was to examine the production of superantigenic toxins in vivo and in vitro in two patients with streptococcal toxic shock syndrome (TSS). In the first patient, a woman with puerperal fever and Streptococcus pyogenes peritonitis, flow cytometry of blood cells and in vitro studies of the isolate showed massive expansion of Vbeta 2-positive T cells corresponding to SpeC production. In the second case, involving a patient with streptococcal TSS and purpura fulminans following non-steroidal anti-inflammatory drug (NSAID) therapy, no Vbeta expansion of T cells was observed in vivo, but the SpeC Vbeta signature was also detected in vitro. In this latter patient, NSAID administration and/or severe disseminated infection might partly explain the absence of Vbeta T cell expansion in vivo. Combined in vivo and in vitro detection of a superantigenic toxin Vbeta signature may be useful to determine which superantigenic toxin is involved in individual cases of streptococcal TSS.
Literature
3.
go back to reference Yu CE, Ferretti JJ (1991) Frequency of the erythrogenic toxin B and C genes (speB and speC) among clinical isolates of group A streptococci. Infect Immun 59:211–215PubMed Yu CE, Ferretti JJ (1991) Frequency of the erythrogenic toxin B and C genes (speB and speC) among clinical isolates of group A streptococci. Infect Immun 59:211–215PubMed
4.
go back to reference Darenberg J, Luca-Harari B, Jasir A et al (2007) Molecular and clinical characteristics of invasive group A streptococcal infection in Sweden. Clin Infect Dis 45:450–458. doi:10.1086/519936 PubMedCrossRef Darenberg J, Luca-Harari B, Jasir A et al (2007) Molecular and clinical characteristics of invasive group A streptococcal infection in Sweden. Clin Infect Dis 45:450–458. doi:10.​1086/​519936 PubMedCrossRef
6.
go back to reference Michie C, Scott A, Cheesbrough J, Beverley P, Pasvol G (1994) Streptococcal toxic shock-like syndrome: evidence of superantigen activity and its effects on T lymphocyte subsets in vivo. Clin Exp Immunol 98:140–144PubMed Michie C, Scott A, Cheesbrough J, Beverley P, Pasvol G (1994) Streptococcal toxic shock-like syndrome: evidence of superantigen activity and its effects on T lymphocyte subsets in vivo. Clin Exp Immunol 98:140–144PubMed
7.
go back to reference Watanabe-Ohnishi R, Low DE, McGeer A et al (1995) Selective depletion of V beta-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. Ontario Streptococcal Study Project. J Infect Dis 171:74–84PubMed Watanabe-Ohnishi R, Low DE, McGeer A et al (1995) Selective depletion of V beta-bearing T cells in patients with severe invasive group A streptococcal infections and streptococcal toxic shock syndrome. Ontario Streptococcal Study Project. J Infect Dis 171:74–84PubMed
9.
go back to reference Matsuda Y, Kato H, Yamada R et al (2003) Early and definitive diagnosis of toxic shock syndrome by detection of marked expansion of T-cell-receptor VBeta2-positive T cells. Emerg Infect Dis 9:387–389PubMed Matsuda Y, Kato H, Yamada R et al (2003) Early and definitive diagnosis of toxic shock syndrome by detection of marked expansion of T-cell-receptor VBeta2-positive T cells. Emerg Infect Dis 9:387–389PubMed
12.
go back to reference Tyler SD, Johnson WM, Huang JC et al (1992) Streptococcal erythrogenic toxin genes: detection by polymerase chain reaction and association with disease in strains isolated in Canada from 1940 to 1991. J Clin Microbiol 30:3127–3131PubMed Tyler SD, Johnson WM, Huang JC et al (1992) Streptococcal erythrogenic toxin genes: detection by polymerase chain reaction and association with disease in strains isolated in Canada from 1940 to 1991. J Clin Microbiol 30:3127–3131PubMed
13.
go back to reference Abe J, Forrester J, Nakahara T, Lafferty A, Kotzin BL, Leung DY (1991) Selective stimulation of human T cells with streptococcal erythrogenic toxins A and B. J Immunol 46:3747–3750 Abe J, Forrester J, Nakahara T, Lafferty A, Kotzin BL, Leung DY (1991) Selective stimulation of human T cells with streptococcal erythrogenic toxins A and B. J Immunol 46:3747–3750
14.
go back to reference Mollick JA, Miller GG, Musser JM, Cook RG, Grossman D, Rich RR (1993) A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with aminoterminal homology to staphylococcal enterotoxins B and C. J Clin Invest 92:710–719. doi:10.1172/JCI116641 PubMedCrossRef Mollick JA, Miller GG, Musser JM, Cook RG, Grossman D, Rich RR (1993) A novel superantigen isolated from pathogenic strains of Streptococcus pyogenes with aminoterminal homology to staphylococcal enterotoxins B and C. J Clin Invest 92:710–719. doi:10.​1172/​JCI116641 PubMedCrossRef
18.
go back to reference Norrby-Teglund A, Muller MP, Mcgeer A et al (2005) Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis 37:166–172. doi:10.1080/00365540500372960 PubMedCrossRef Norrby-Teglund A, Muller MP, Mcgeer A et al (2005) Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis 37:166–172. doi:10.​1080/​0036554050037296​0 PubMedCrossRef
20.
go back to reference Middelveld RJ, Alving K (2000) Synergistic septicemic action of the gram-positive bacterial cell wall components peptidoglycan and lipoteichoic acid in the pig in vivo. Shock 3:297–306 Middelveld RJ, Alving K (2000) Synergistic septicemic action of the gram-positive bacterial cell wall components peptidoglycan and lipoteichoic acid in the pig in vivo. Shock 3:297–306
21.
go back to reference Rossi Paccani S, Boncristiano M, Baldari CT (2003) Molecular mechanisms underlying suppression of lymphocyte responses by nonsteroidal antiinflammatory drugs. Cell Mol Life Sci 60:1071–1083PubMed Rossi Paccani S, Boncristiano M, Baldari CT (2003) Molecular mechanisms underlying suppression of lymphocyte responses by nonsteroidal antiinflammatory drugs. Cell Mol Life Sci 60:1071–1083PubMed
23.
go back to reference Proft T, Arcus VL, Handley V, Baker EN, Fraser D (2001) Immunological and biochemical characterization of streptococcal pyrogenic exotoxins I and J (SPE-I and SOE-J) from Streptococcus pyogenes. J Immunol 166:6711–6719PubMed Proft T, Arcus VL, Handley V, Baker EN, Fraser D (2001) Immunological and biochemical characterization of streptococcal pyrogenic exotoxins I and J (SPE-I and SOE-J) from Streptococcus pyogenes. J Immunol 166:6711–6719PubMed
Metadata
Title
In vivo and in vitro detection of a superantigenic toxin Vbeta signature in two forms of streptococcal toxic shock syndrome
Authors
D. Thomas
T. Perpoint
O. Dauwalder
G. Lina
B. Floccard
J.-C. Richard
A. Bouvet
D. Peyramond
B. Allaouchiche
C. Chidiac
F. Vandenesch
J. Etienne
T. Ferry
Publication date
01-06-2009
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 6/2009
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-008-0671-7

Other articles of this Issue 6/2009

European Journal of Clinical Microbiology & Infectious Diseases 6/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.